Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acceleron To Be Next M&A Target With Rumored $11bn Deal

BMS Seen As Most Likely Suitor

Executive Summary

The Cambridge, MA-based biotech has one blockbuster-tipped drug already on the market, with another in pivotal studies.

You may also be interested in...



Acceleron Investors Want Merck To Pay More, Ask Company To Wait For Better Offer

Avoro Capital, Holocene Advisors and Darwin Global say that Acceleron should sell later for a higher price based on forthcoming data or Merck should raise its bid above $180 per share.

Merck’s $11.5bn Acceleron Buy Partially Fills Future Keytruda Revenue Gap

The company announced the biggest biopharma M&A deal of the year so far, but Merck will need more large deals to manage declining sales when its top-selling product faces biosimilars in 2028. 

Merck Closes In On Acceleron But BMS And Anti-Trust Regulators Could Be Obstacles

Biopharma M&A has had a quiet year so far but could heat up if rivals start vying for the biotech company.

Related Content

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145132

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel